NEW YORK (GenomeWeb News) - The National Institutes of Health will map lung, brain, and ovarian cancers for its Cancer Genome Atlas project, the agency said today.
As part of the pilot phase, the NIH plans to map genomic changes in the cancers.
The agency selected the three cancers because the available biospecimen collections met TCGA’s “scientific, technical, and ethical” requirements, the NIH said.
Boston’s Brigham and Women’s Hospital will supply lung cancer biospecimens from its Lung Cancer Tissue Bank of the Cancer and Leukemia Group B clinical trials group; the glioblastoma biospecimens for brain tumors will come from Houston’s MD Anderson Cancer Center; and the Gynecologic Oncology Group tissue bank at the Children's Hospital of Ohio State University will provide the ovarian cancer biospecimens.
The International Genomics Consortium, part of the Translational Genomics Research Institute, will manage TCGA’s BCR, NIH said. The BCR will collect, store, process, and distribute biomolecules from cancerous and normal samples to the Cancer Genome Characterization Centers and Genome Sequencing Centers for genomic analysis. The centers have not yet been selected.
The National Cancer Institute and the National Human Genome Research Institute launched TCGA in December 2005
. The three-year project will use large-scale genome analysis technologies to map genomic changes.